LIVE: Current Concepts in Molecular Testing for HR+/HER2- Metastatic Breast Cancer
Description:
This webinar series will provide an overview of molecular genetic testing methods and current best practices for HR+/HER2- breast cancer, emphasizing mutations in PIK3CA, AKT1, PTEN and ESR1.Learning Objectives:
- Recognize the importance of mutation testing for patients with HR+/HER2- metastatic breast cancer
- Describe best practices for molecular testing in metastatic breast cancer
Working Group:
Katherine B. Geiersbach, M.D. (chair)
Mayo Clinic
Karthik Giridhar, M.D.
Mayo Clinic
Shuko Harada, M.D.
University of Alabama at Birmingham
Eric Vail, M.D.
Cedars-Sinai Medical Center
Paul M. Waring, MBBS, Ph.D.
Translational Pathology Consulting Services
This webinar series is planned and coordinated by the Metastatic Breast Cancer Webinar Series Working Group, and supported by the AMP Training & Education Committee.
Schedule of Live Webinars:
Webinar #1: Introduction to Molecular Biomarkers: Evidence and Guidelines
Speakers: Eric Vail, M.D. & Paul M. Waring, MBBS, Ph.D.
Date: October 21, 2025 | 4PM ET
Webinar #2: Molecular Testing Strategies and Evaluation of Assay Performance
Speakers: Katherine B. Geiersbach, M.D. & Shuko Harada, M.D.
Date: October 27, 2025 | 4PM ET
Webinar #3: Applying Molecular Testing in Practice with Case Discussions and Expert Panel
Speaker: Karthik Giridhar, M.D.
Date: October 30, 2025 | 2PM ET
Duration: three 1-hour webinars
Target Audience: Molecular pathologists, surgical pathologists, clinical oncologists, trainees, laboratory technical staff, and clinicians.
Certificate: Learners will be awarded a Certificate of Attendance at the conclusion of the course. CME or CMLE credits are NOT available for this educational series.
This activity was funded by AstraZeneca; the content was developed by AMP.